Study on the Relationship Between Normalization of Tumor Microvessels and CA9 for Rh-Endostatin to Inhibit Lewis Lung Cancer

HE Lang, SUN Yong-hong, LIU Kang. et al

Abstract

To explore the relationship between normalization of tumor microvessels and CA9 for rh-Endostatin to inhibit Lewis lung cancer (LLC) and the expression level of CA9 in LLC. Methods Lewis cells of logarithmic growth phase were collected and made into 1×106 mL-1 cell suspensions were prepared. The transplanted tumor model of LLC was established on C57/BL6 mice by injected 0.2 mL cell suspensions/mice into 40 C57/BL6 mice. 40 LLC mice were randomly divided into control group and rh-ES group (20 mice per group). Control group experienced treatment of intraperitoneal injection (ip) for 0.2 mL NS/d, while rh-ES group was treated for 5 mg rh-ES/(kg·d) from the first to the ninth day. The samples of 5 mice were obtained from day 2, day 4, day 6 and day 9 after treatment in control group or rh-ES group, respectively. CA9 was tested by IHC in LLC and paracancerous tissues and estimated by RT-PCR and ELISA in the each time point of both rh-ES group and control group, respectively. Results The transplanted tumor model of LLC on C57/BL6 mice was established successfully. The expression of CA9 decreased on day 4 and day 6 in rh-ES group estimated by RT-PCR and ELISA, which indicated some great significance when compared with day 2, day 9 in rh-ES group and day 4, day 6 in control group (P<0.05), and the expression of CA9 in day 2, day 4, day 6, day 9 tested by IHC was higher in

 

Keywords: rh-Endostatin, Lewis lung cancer, CA9 

 

Full Text:

PDF


References


FOLKMAN J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol.2002.29(6 Suppl 16):15-18.

AUSIAUX R. BAUDELET C, JORDAN BF. et al. Thalidomide radiosensitizes tumors through early changes in the tumor, microenvironment. Clin Cancer Res, 2005, 11 (2Ptl):743-750.

HURWITZ H, FEHRENBAEHER L,NOVOTNY W.et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004 , 350 ( 23 ): 2335-2342.

WINKLER F, KOZIN SV, TONG RT, et al. Kinetics of vascular nor realization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation,angiopoietin- l,and matrix metalloproteinases. Cancer Cell, 2004, 6 ( 12) :553-563.

JAIN RK. Normalizing tumor vasculature with anti- angiogenic therapy; a new paradigm for combination therapy. Nat Med,2001,7(9) :987-989.

OLIVE PL, AQUINO-PARSONS C.MACPHAIL et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res,2001,61(24) :8924-8929.

LEE CG, HEIJN M, DI TOMASO E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res, 2000,60(19):5565-5570.

RAHMAN MA, DHAR DK, YAMAGUCHI E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis С virus- positive cases. Clin Cancer Res,2001 .7(5): 1325-1332.

STEFANSSON IM, SALVESEN HB, AKSLEN LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res,2006,66(6) ;3303-3309.

WELEN K, JENNBACKEN K. TESAN T, et al. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis, 2009,12(1);41 -46.

PENG F, XU Z, WANG J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLos One, 2012, 7 (4) ; e34646 [2016-12- 21]. http;//dx. doi. org/10. 1371/journal, pone. 0034646.

GOEL S, DUDA DG. XU L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev,2011,91(3) : 1071-1121.

TONG RT, BOUCHER Y, KOZIN SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 2004, 64(ll):3731-3736.

HURWITZ H, FEHRENBAEHER L,NOVOTNY W.et al. Bevacizumab plus irinotecan, fluorouracil. and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004 , 350 ( 23 ): 2335-2342.

SHIN HJ, KHO SB. JUNG DC, et al. Carbonic anhydrase IX ( CA9 ) modulates tumor-associated cell migration and invasion. J Cell Sci,2011,124 (Pt7): 1077-1087.

FERRARA N, HILLAN KJ, GERBER HP, et al. Discovery and development of bevacizumab. an anti-VEGF antibody for treating cancer. Nat Rev Drug, 2004 , 3( 5); 391- 400.

NAKAMURA J, KITAJIMA Y, KAI К .etal. Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer. Am J Pathol,2011,178(2) ;515-524.

STEWART GD, O' MAHONY FC, LAIRD A, et al. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol,2014, 66(5);956-963.

LLIE M, HOFMAN V, ZANGARI J, et al. Response of CA IV and CA to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients. Lung Cancer,2013,82(1): 16-23.


Refbacks

  • There are currently no refbacks.